Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed Plus Cisplatin in Extensive Small Cell Lung Cancer
NCT00475657Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2007
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pemetrexed in small cell lung cancer (SCLC), sponsored by Eli Lilly and Company. Started Oct 2007; status: terminated.
02
Drugs
pemetrexed
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00475657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00475657.